HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Approximately 40% to 80% of patients receiving pertuzumab-directed therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer will develop chemotherapy-induced diarrhea (CID). Loperamide and octreotide are frequently used to treat CID after diarrhea occurs, but neither is used prophylactically or targets the underlying mechanism. Previous studies suggest blocking epidermal growth factor receptor may cause excess chloride secretion, resulting in diarrhea. Crofelemer is derived from the red latex of the Croton lechleri tree, blocks gastrointestinal cystic fibrosis transmembrane regulator and calcium-activated chloride channels, and is U.S. Food and Drug Administration approved for relief of diarrhea in HIV/AIDS patients on anti-retroviral therapy. Crofelemer is not systemically absorbed, has relatively few side effects, and presents a targeted approach at preventing CID in patients receiving pertuzumab-based therapy. HALT-D (DiarrHeA Prevention and ProphyLaxis with Crofelemer in HER2-Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel with or without Carboplatin, NCT02910219) is a phase II, randomized, open-label trial that aims to recruit 46 patients from 3 MedStar sites. Adults with HER2-positive breast cancer being treated with trastuzumab, pertuzumab, and docetaxel or paclitaxel (THP) or trastuzumab, pertuzumab, docetaxel, and carboplatin (TCHP) will be randomized to receive crofelemer or no medication for diarrhea prophylaxis. The primary endpoint is incidence of all grade diarrhea for ≥ 2 consecutive days during cycles 1 to 2 of THP or TCHP. Secondary endpoints include overall incidence, duration, and severity of diarrhea; time to onset of diarrhea; use of other anti-diarrheal medications; stool frequency and consistency; and quality of life. HALT-D will provide important information about the feasibility and tolerability of crofelemer in preventing diarrhea for patients receiving THP or TCHP.
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Jennifer J
JJ
Gao
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC.
Ming
M
Tan
Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
Paula R
PR
Pohlmann
Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC. Electronic address: Sandra.Swain@georgetown.edu.
Sandra M
SM
Swain
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage; D003967:Diarrhea / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D044945:Proanthocyanidins / Q000627:therapeutic use*; D011379:Prognosis; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab / Q000008:administration & dosage; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D044945:Proanthocyanidins; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin; C485206:pertuzumab; D000068878:Trastuzumab; D017239:Paclitaxel; C546704:crofelemer
Breast cancer; Chemotherapy induced diarrhea; Crofelemer; HER2; Pertuzumab
Lancet Oncol. 2014 Sep;15(10):e447-60
25186048
Cancer Cell. 2010 Aug 9;18(2):160-70
20708157
Lancet Oncol. 2012 Jan;13(1):25-32
22153890
Ann Oncol. 2013 Sep;24(9):2278-84
23704196
HIV Clin Trials. 2013 Nov-Dec;14 (6):261-73
24334179
Curr Oncol. 2012 Jun;19(Suppl 1):S59-63
22787412
N Engl J Med. 2012 Jan 12;366(2):109-19
22149875
Cancer Treat Rev. 2015 Jul;41(7):646-52
26073491
Crit Rev Oncol Hematol. 2014 May;90(2):165-79
24373918
Curr Oncol. 2014 Dec;21(6):329-36
25489260
Cancer Chemother Pharmacol. 2013 Dec;72(6):1205-12
24077916
J Clin Oncol. 2015 Feb 10;33(5):442-7
25547504